Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

January 28, 2026 updated by: SystImmune Inc.

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

BL-B01D1-LUNG-101 is a global, multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics , and initial efficacy of BL-B01D1 in participants with metastatic or unresectable NSCLC and Other Solid Tumors.

This study will be conducted in two different dosing schedules (Cohort A and Cohort B) and three parts (dose escalation, dose finding and dose expansion). Cohort A will be dosed on Day 1 and Day 8 of a continuous 21-day treatment cycle. Cohort B will be dosed on Day 1 of a continuous 21-day treatment cycle. Each Cohort has different dose groups.

Study Type

Interventional

Enrollment (Estimated)

470

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Lyon, France, 69373
      • Paris, France, 75013
        • Recruiting
        • Groupe Hospitalier Pitie-Salpetriere
        • Principal Investigator:
          • Aurore VOZY, MD
        • Contact:
      • Saint-Herblain, France, 44805
        • Recruiting
        • Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
        • Principal Investigator:
          • Sandrine Hiret, MD
        • Contact:
      • Villejuif, France, 94800
  • Italy
      • Candiolo, Italy, 10060
        • Recruiting
        • Fondazione del Piemonte per l'Oncologia IRCC Candiolo
        • Principal Investigator:
          • Vanesa Gregorc, MD
        • Contact:
      • Rozzano, Italy, 20089
        • Recruiting
        • IRCCS Istituto Clinico Humanitas, Cancer Center
        • Principal Investigator:
          • Matteo Simonelli, MD
        • Contact:
  • Japan
      • Chūōku, Japan, 104-0045
        • Recruiting
        • National Cancer Center Hospital
        • Contact:
        • Principal Investigator:
          • Noboru Yamamoto, MD
  • Spain
      • Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron
        • Principal Investigator:
          • Enriqueta Felip Font, MD
        • Contact:
      • Barcelona, Spain, 8041
        • Recruiting
        • Hospital de la Santa Creu i Sant Pau
        • Contact:
        • Principal Investigator:
          • Margarita Majem Tarruella, MD
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
        • Principal Investigator:
          • Luis Paz-Ares Rodriguez, MD
        • Contact:
      • Madrid, Spain, 28007
        • Recruiting
        • Hospital Beata Maria Ana
        • Contact:
        • Principal Investigator:
          • Javier Cortes, MD
      • Madrid, Spain, 28040
        • Recruiting
        • START Madrid / Hospital Universitario Fundacion Jimenez Diaz
        • Contact:
        • Principal Investigator:
          • Ester Garcia Lorenzo, MD
      • Madrid, Spain, 28050
        • Recruiting
        • START Madrid / Centro Integral Oncologico Clara Campal
        • Contact:
        • Principal Investigator:
          • Maria Jose de Miguel Luken, MD
      • Piqueras, Spain, 26006
        • Not yet recruiting
        • START Rioja
        • Contact:
          • Maria Jose de Miguel Luken
        • Principal Investigator:
          • Maria Jose de Miguel Luken, MD
      • Seville, Spain, 41009
        • Recruiting
        • Hospital Universitario Virgen Macarena
        • Principal Investigator:
          • David Vicente Baz, MD
        • Contact:
  • United States
    • California
      • Beverly Hills, California, United States, 90211
      • Duarte, California, United States, 91010
        • Recruiting
        • City of Hope Cancer Center
        • Contact:
        • Principal Investigator:
          • Adam Rock, MD
      • Irvine, California, United States, 92612
        • Not yet recruiting
        • Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Principal Investigator:
          • Cathleen Park, MD
        • Contact:
      • Irvine, California, United States, 92612
        • Not yet recruiting
        • Chao Family Comprehensive Cancer Care and Ambulatory Care
        • Principal Investigator:
          • Cathleen Park, MD
        • Contact:
          • Cathleen Park, MD
      • Orange, California, United States, 92868
        • Recruiting
        • University of California Irvine Medical Center
        • Principal Investigator:
          • Cathleen Park, MD
        • Contact:
      • Santa Monica, California, United States, 90404
        • Recruiting
        • UCLA Santa Monica
        • Principal Investigator:
          • Jonathan Goldman, MD
        • Contact:
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • University of Colorado Cancer Center
        • Principal Investigator:
          • Tejas Patil, MD
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Recruiting
        • Yale University, Yale Cancer Center
        • Principal Investigator:
          • Scott Gettinger, MD
        • Contact:
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20007
    • Florida
      • Miami, Florida, United States, 33125
        • Recruiting
        • Sylvester Comprehensive Cancer Center
        • Principal Investigator:
          • Gilberto Lopes, MD
        • Contact:
      • Orlando, Florida, United States, 32827
        • Recruiting
        • Sara Cannon Research Institute Lake Nona
        • Principal Investigator:
          • Cesar Perez Batista, MD
        • Contact:
      • Port Saint Lucie, Florida, United States, 34952
        • Recruiting
        • Hematology - Oncology Associates of the Treasure Coast
        • Principal Investigator:
          • Nicholas Iannotti, MD
        • Contact:
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern University Feinberg School of Medicine
        • Contact:
        • Principal Investigator:
          • Young Chae, MD
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Recruiting
        • University of Iowa Hospital and Clinics
        • Principal Investigator:
          • Sneha Phadke, MD
        • Contact:
    • Kentucky
      • Louisville, Kentucky, United States, 40202
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Dana-Farber Cancer Institute
        • Contact:
        • Principal Investigator:
          • Janne Pasi, MD, PhD
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center Head Neck Services
        • Principal Investigator:
          • Helena Yu, MD
        • Contact:
    • South Carolina
      • Greenville, South Carolina, United States, 29605
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Sarah Cannon - Tennessee Oncology
        • Principal Investigator:
          • Melissa Johnson, MD
        • Contact:
    • Texas
      • Houston, Texas, United States, 77030
      • Houston, Texas, United States, 77030
        • Recruiting
        • University of Texas M.D. Anderson Cancer Center
        • Principal Investigator:
          • Xiuning Le, MD
        • Contact:
    • Virginia
      • Fairfax, Virginia, United States, 22031
    • Washington
      • Seattle, Washington, United States, 98109
        • Recruiting
        • University of Washington Fred Hutchinson
        • Principal Investigator:
          • Christina Baik, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  1. Signed the informed consent voluntarily and agreed to follow the program requirements
  2. Either sex
  3. Age: ≥18 years
  4. Has a life expectancy of ≥3 months

  5. Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: NSCLC, HER2 - breast cancer, esophageal cancer, SCLC, NPC, and HNSCC.

    Has documented locally advanced or metastatic HER2 negative (by immunohistochemistry [IHC], score of 0 or 1) Hormone Receptor (HR) positive (HER2-, HR+) OR HER2 negative (IHC score of 0 to 2) HR negative breast cancer (HER2-, HR-) as per ASCO CAP criteria (ASCO CAP 2023; Wolff et al. 2023), not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease, must have received 1 prior line of chemotherapy for advanced disease and, when applicable and if approved in that region, a PD-1/PD-L1 inhibitor, either given concurrently or sequentially. When appropriate, must have progression on at least 1 prior line of hormonal therapy with or without a targeted therapy (such as CDK4/6, mTOR, or PI3-K inhibitors) administered for treatment of metastatic disease.

    In Dose Escalation and Dose finding portions of the study, for triple-negative breast cancer (TNBC, HER2-/HR-) participants must have received PARP inhibitors if a BRCA mutation is present and sacituzumab govitecan as second line treatment. Participants who are HER2 low must have received trastuzumab deruxtecan.

  6. Agree to provide archived tumor samples (tissue block or slides) from primary or metastatic sites within 2 years. In the event that no archival tissue is available a fresh tissue biopsy is highly encouraged but not mandatory.
  7. Has at least one measurable lesion based on RECIST V1.1 (with the exception of Prostate adenocarcinoma cohort, where subjects with bone metastasis are allowed)
  8. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1
  9. Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum or plasma amylase/lipase, and elevated blood glucose; except for toxicity that the investigator determined to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.)
  10. Has no serious cardiac dysfunction, left ventricular ejection fraction ≥50%
  11. Has adequate organ function before registration, defined as: a) Marrow Function: Absolute neutrophil count (ANC) ≥1.2×109 /L, Platelet count ≥100×109 /L, Hemoglobin (Hb) ≥90 g/L b) Hepatic function: Total bilirubin（TBIL≤1.5 ULN, AST and ALT without liver metastasis ≤2.5 ULN, AST and ALT with liver metastasis ≤5.0 ULN c) Renal function: Creatinine clearance ≥50 mL/min (According to the Cockcroft and Gault equation)
  12. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5 ULN
  13. Urinary protein ≤2+ or ≤1000mg/24 hours
  14. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months for females and 4 months for males after the last dose of study treatment. An additional contraceptive method, such as a barrier method like a condom is required.
  15. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female subjects are considered WOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman >45 years old in the absence of other biological or physiological causes. In addition, females <55 years old must have a serum follicle stimulating hormone (fsh) level > 40 mIU/mL to confirm menopause.

  16. For subjects with NSCLC (EGFR mutation):

    a) Evidence of documented EGFR TKI-sensitizing deletion mutation in EGFR Exon 19 (ex19del) or leucin-arginine substitution point mutation in EGFR Exon 21 (ex21L858R), the serine-isoleucine mutation in EGFR Exon 20 (ex20S768I), the leucine-glutamine substitution mutation in Exon 21 (ex21L861Q), or the glycine substitution (with alanine, cysteine, or serine) mutation in Exon 18 (ex18G719X) at or after the time of disease diagnosis and prior to initiation of treatment.

  17. For Triple-Negative Breast Cancer (TNBC, HER2-/HR-):

    a) Histologically or cytologically confirmed and documented locally advanced, recurrent inoperable or metastatic TNBC

  18. For Esophageal adenocarcinoma

    a) Has locally advanced or metastatic adenocarcinoma cell carcinoma of the esophagus or esophagogastric junction cancers, not amenable to curative surgery or radiation with documentation of radiological disease progression after one line of fluoropyrimidine and/or platinum-based chemotherapy treatment regimen for locally advanced or metastatic disease.

    NOTE: Prior therapies such as trastuzumab, zolbetuximab, or IOs are allowed in the study.

  19. For Prostate adenocarcinoma

    a) Subject has metastatic castration-resistant prostate cancer (mCRPC) after progression on/after an androgen receptor pathway inhibitors (ARPI) treatment, such as abiraterone, enzalutamide, apalutamide and darolutamide.

    Note: No prior chemotherapy including docetaxel is allowed Prior treatment with lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is allowed. Enrollment will be capped for lutetium Lu 177 vipivotide tetraxetan-naive participants at approximately 20 or participants with prior lutetium Lu 177 vipivotide tetraxetan treatment at approximately 20.

  20. For NSCLC (EGFR wild type) with squamous histology

    1. Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease with predominantly squamous cell histology
    2. Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1).
    3. Progressed or intolerant to one line of platinum-based chemotherapy with α-PD-1/L1 monoclonal antibody given either concurrently or sequentially.

  21. For NSCLC (EGFR wild type) with adenocarcinoma histology

    1. Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease with predominantly adenocarcinoma histology
    2. Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1).

    Progressed or intolerant to one line of platinum-based chemotherapy with α-PD-1/L1 monoclonal antibody given either concurrently or sequentially.

  22. Ovarian adenocarcinoma

    a) Has histologic documentation of epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed on or after a previous platinum-containing chemotherapy with or without a PARP inhibitor.

    Note: participants with platinum-sensitive or platinum resistant recurrent ovarian cancer (PSR) are eligible. However, enrollment will be capped for platinum-sensitive or platinum resistant participants at approximately 20 each.

    Prior bevacizumab treatment is allowed.

  23. Endometrial carcinoma

    a) Has relapsed, advanced and/or metastatic endometrial carcinoma, who have progressed on or after prior platinum-based chemotherapy with or without immuno-oncology (IO) treatment

  24. For Cervical carcinoma Has relapsed, advanced and/or metastatic cervical carcinoma, who have progressed on or after prior platinum-based chemotherapy with or without immuno-oncology (IO) treatment

Exclusion criteria:

  1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anti-tumor therapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first administration; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration
  2. Participants with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable angina pectoris etc;
  3. Subjects with prolonged QT interval (QTc >470 msec), complete left bundle branch block, Grade 3 atrioventricular block
  4. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)
  5. Other malignant tumors were diagnosed within 5 years prior to the first administration with the following exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after radical resection
  6. Participants with poorly controlled hypertension by two kinds of antihypertensive drugs (systolic blood pressure>150 mmHg or diastolic blood pressure>100 mmHg)
  7. Participants have Grade 3 lung disease defined according to NCI-CTCAE v5.0, a history of interstitial lung disease (ILD)/ pneumonitis
  8. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening; Infusion set-related thrombosis is excluded
  9. Participants with primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to dosing with the investigational product (IP). Participants on low dose corticosteroids (<20 mg prednisone or equivalent/day) may participate.
  10. Participants who have a history of allergies to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-B01D1
  11. Participants have a history of autologous or allogeneic stem cell transplantation (Allo-HSCT)
  12. Has received treatment with anthracyclines with a cumulative dose exceeding 360 mg/m2
  13. Participants with ≥ Grade 2 hypokalemia (low concentration of potassium in the blood) according to CTCAE v5.0 (Grade 1: participant asymptomatic with potassium levels <LLN - 3.0 mmol/L or equivalent)
  14. Known Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active Hepatitis B virus infection (HBV-DNA copy number> the lower limit of detection) or active Hepatitis C virus infection (HCV antibody positive and HCV-RNA > the lower limit of detection)
  15. Participants with active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis.
  16. Received an investigational drug within 4 weeks, or two half-lives (whichever is longer) prior to first dose of study treatment
  17. Participants who are pregnant or breastfeeding
  18. Other conditions that the investigator believes may make the subject not suitable for participating in this clinical trial.

  19. Participants who have received prior therapy with any ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload (all dose expansion cohorts with exception of TNBC noted below).

    Note: For TNBC dose expansion cohort, participants with prior ADC therapy targeting HER3 and EGFR or a topoisomerase I inhibitor, such as sacituzumab govitecan may be enrolled with Sponsor consultation prior to enrollment

  20. For NSCLC EGFRmut:

    1. Participants treated with more than two systemic chemotherapies prior to randomization.

      NOTE: Progression of disease within 12 months after receiving neoadjuvant and adjuvant chemotherapies is considered 1 prior systemic chemotherapy

    2. Previously documented EGFR Exon 20 insertion mutations as primary EGFR mutations

  21. For Triple-Negative Breast Cancer (TNBC, HER2-/HR-):

    a) Participants treated with more than two systemic chemotherapies prior to randomization.

    NOTE: Progression of disease within 12 months after receiving neoadjuvant and adjuvant chemotherapies is considered 1 prior systemic chemotherapy

  22. For Esophageal Carcinoma a) Participants received more than 1 prior line of systemic chemotherapy therapy for locally advanced or metastatic disease. NOTE: this limit only applies to prior systemic chemotherapy.

  23. For Prostate adenocarcinoma:

    a) Prior treatment with systemic chemotherapy.

  24. For NSCLC with EGFR WT squamous or adenocarcinoma histology: a) Participants received more than 1 prior line of systemic chemotherapy for locally advanced or metastatic disease
  25. For Ovarian Carcinoma a) Participants received more than 1 prior line of systemic chemotherapy. Re-treatment with platinum-based chemotherapy is considered one line of therapy. Prior hormonal therapy is permitted.
  26. For Endometrial Carcinoma a) Participants received more than 1 prior line of systemic chemotherapy. Re-treatment with platinum-based chemotherapy is considered one line of therapy. Prior hormonal therapy is permitted.
  27. For Cervical Carcinoma a) if received more than 1 prior line of systemic chemotherapy. Re-treatment with platinum-based chemotherapy is considered one line of therapy.

Notes: Re-treatment with platinum-based chemotherapy is considered one line of therapy.

Note: A participant who does not meet this exclusion criterion may be allowed into the study pending the sponsor's approval, based on current accrual within this dose expansion cohort.

Note: There is no limit on the number of prior lines of non-chemotherapy regimens. ADCs with cytotoxic payloads are considered a line of chemotherapy. For any expansion cohorts, if only limited number of patients can be enrolled with 1 prior line of chemotherapy, the Sponsor has the option to allow participants with more than 1 prior line of chemotherapy to be enrolled, upon Sponsor's approval.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BL-B01D1 administered Day 1 and Day 8 per cycle
BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks
Drug: BL-B01D1
BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
Experimental: BL-B01D1 administered Day 1 per cycle
BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks
Drug: BL-B01D1
BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participants with Dose-limiting toxicities
Time Frame: One year

Measuring the number of patients Dose-limiting toxicities (DLTs). A DLT is defined as any of the following events that are not clearly due to the underlying disease or extraneous causes:

Hematological toxicities:

  • Grade 4 neutrophil count decreased lasting >7 days
  • Grade ≥3 febrile neutropenia
  • Grade ≥3 platelet count decreased with clinically significant hemorrhage.

Non-Hematological toxicities:

  • Death
  • Hy's law cases
  • Grade ≥3 non-hematological toxicities,
One year
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs),
Time Frame: One year
Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)
One year
Participants with abnormal physical examination findings
Time Frame: One year
Measure the number of participants with abnormal physical examination findings.
One year
Participants with ability to care for themselves, daily activity, and physical activity
Time Frame: One year
Measure the change in participants with Eastern Clinical Oncology Group (ECOG) Scale of Performance Status. The scale is 0-4 with 0 being the fully active (best outcome) and 4 being completely disabled (worst outcome)
One year
Participants with abnormal ECG reading
Time Frame: One year
Measure the number of participants with abnormal ECG parameters
One year
Participants with abnormal lab results
Time Frame: One year
Measure the number of participants with abnormal clinical laboratory values
One year
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC
Time Frame: One year
Determine the highest BL-B01D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-B01D1 dose administered in the event and MTD cannot be defined.
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cmax of BL-B01D1
Time Frame: One year
Calculate maximum (peak) observed concentration of BL-B01D1
One year
Cmax of anti-EGFR×HER3 antibody
Time Frame: One year
Calculate maximum (peak) observed concentration of anti-EGFR×HER3 antibody
One year
Cmax of free payload ED-04
Time Frame: One year
Calculate maximum (peak) observed concentration of free payload ED-04
One year
Tmax of BL-B01D1
Time Frame: One year
Calculate time of maximum observed concentration of BL-B01D1
One year
Tmax of anti-EGFR×HER3 antibody
Time Frame: One year
Calculate time of maximum observed concentration of anti-EGFR×HER3 antibody
One year
Tmax of free payload ED-04
Time Frame: One year
Calculate time of maximum observed concentration of free payload ED-04
One year
AUC(0-8) of BL-B01D1
Time Frame: One year
Calculate area under the serum concentration-time curve of BL-B01D1 from time 0 to 8 hours
One year
AUC(0-8) of anti-EGFR×HER3 antibodies
Time Frame: One year
Calculate area under the serum concentration-time curve of anti-EGFR×HER3 antibodies from time 0 to 8 hours
One year
AUC(0-8) of free payload ED-04
Time Frame: One year
Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours
One year
AUC(last) of BL-B01D1
Time Frame: One year
Calculate area under the serum concentration-time curve up of BL-B01D1 to the last quantifiable time
One year
AUC(last) anti-EGFR×HER3 antibodies
Time Frame: One year
Calculate area under the serum concentration-time curve up of anti-EGFR×HER3 antibodies to the last quantifiable time
One year
AUC(last) of free payload ED-04
Time Frame: One year
Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time
One year
Overall Response Rate (ORR)
Time Frame: One year
To assess the clinical efficacy of BL-B01D1 as measured by ORR using RECIST criteria v 1.1
One year
Disease Control Rate (DCR)
Time Frame: One year
To assess the clinical efficacy of BL-B01D1 as measured by DCR using RECIST criteria v 1.1
One year
Time To Response (TTR)
Time Frame: One year
To assess the clinical efficacy of BL-B01D1 as measured by TTR using RECIST criteria v 1.1
One year
Progression-Free Survival (PFS),
Time Frame: One year
To assess the clinical efficacy of BL-B01D1 as measured by PFS using RECIST criteria v 1.1
One year
Overall Survival (OS).
Time Frame: One year
To assess the clinical efficacy of BL-B01D1 as measured by OS using RECIST criteria v 1.1
One year
Antitumor Activity
Time Frame: One year
To investigate the antitumor activity of BL-B01D1 as evaluated using RECIST Version 1.1
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SystImmune Inc.

Investigators

  • Study Director: Jimmy Zhao, MD, PhD, SystImmune Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 8, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

March 21, 2028

Study Registration Dates

First Submitted

July 12, 2023

First Submitted That Met QC Criteria

August 1, 2023

First Posted (Actual)

August 9, 2023

Study Record Updates

Last Update Posted (Actual)

January 29, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BL-B01D1-LUNG-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on BL-B01D1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe